Showing 324 results

Filters Content type: News, Editors' picks Topic: Changing treatment

A change of HIV treatment may be necessary because of side-effects, the development of drug resistance, treatment not being fully effective or because of interactions between HIV drugs and other medications.

Resistance

Proviral DNA resistance testing allows treatment switches without viral rebound

News
22 January 2020
Changing treatment

Lipid increases after switching from TDF to TAF are reversible when treatment is changed back to TDF

News
10 December 2019
Changing treatment

Caveat emptor: Seven things every patient should know about switching from efavirenz to dolutegravir

Editor's pick
Spotlight
25 November 2019
Treatment simplification strategies

Options for two-drug simplification expand

News
14 November 2019
Treatment simplification strategies

Jitters Over New Two-Drug HIV Regimens

Editor's pick
Medscape (requires free registration)
12 November 2019
Side effects

Weight gain after switching to integrase inhibitor treatment is small in Dutch and Swiss cohorts

News
11 November 2019
Bone & joint problems

Switching from TDF to TAF associated with improvements in bone mineral density in people over 60

News
4 November 2019
Viral load

Point-of-care viral load testing results in more switches from failing treatment

News
26 September 2019
Changing treatment

FDA Expands Indications for Pifeltro and Delstrigo for HIV

Editor's pick
Medscape (requires free registration)
23 September 2019
Cardiovascular disease

Switching Back to Older Tenofovir Improves Lipid Levels

Editor's pick
POZ
12 September 2019
Changing treatment

‘Alarming’ rates of second-line HIV treatment failure in sub-Saharan Africa

Editor's pick
Avert
22 August 2019
Adherence

Directly observed therapy can be a useful tool in caring for people with HIV treatment failure

News
13 August 2019
Kidney problems

Change in Kidney Function After TDF-to-TAF Switch: Who Benefits Most?

Editor's pick
NATAP
10 August 2019
Changing treatment

High efficacy from switching to bictegravir/F/TAF in virally suppressed participants – including analyses by baseline drug resistance

Editor's pick
i-Base
2 August 2019
HIV treatment for children & young people

Without frequent viral load monitoring dolutegravir-based regimens not the best choice for African youth on failing ART

News
30 July 2019
Changing treatment

Biktarvy Suppresses HIV Well in Women and Those With Drug Resistance

Editor's pick
POZ
29 July 2019
Treatment-experienced people

Fostemsavir salvage therapy continues to look good at 96 weeks

News
29 July 2019
Treatment simplification strategies

Dolutegravir dual therapy works well for both first line and maintenance treatment

News
29 July 2019
Treatment simplification strategies

Four days on, three days off HIV treatment as effective as continuous therapy, French study finds

News
25 July 2019
Pharmaceutical industry

GSK touts new Dovato switching data. Is it enough to shake Gilead's HIV lead?

Editor's pick
FiercePharma
11 July 2019
Changing treatment

Drug-Resistance Mutations May Curb Efficacy of Dolutegravir-Based Regimens in Zimbabwe Teens With HIV

Editor's pick
Medscape (free registration required)
7 July 2019
New & experimental HIV treatments

1 Year After Approval: How Does D/C/F/TAF Measure Up?

Editor's pick
Contagion Live
1 July 2019
Treatment-experienced people

ART for treatment-experienced people with virological failure can omit NRTIs if three active drugs available

News
13 June 2019
Health monitoring in resource-limited settings

Significant health gains from faster switching to second-line ART in sub-Saharan Africa

News
29 May 2019